Health Care Closes +0.4% as Large Drugmakers Mask Broad Weakness

The Health Care sector finished +0.4% on Friday, October 30, but the modest headline number masked significant internal division. While 51.8% of the sector's graded weight sits in companies graded A or B, market breadth was thin, with only 30.5% of its member stocks advancing. An equal-weighted measure of the group ended -1.0%, showing that smaller names broadly retreated. The sector's exchange-traded fund, Health Care Select Sector SPDR Fund (XLV), closed +0.5%. Driving the cap-weighted strength was Regeneron Pharmaceuticals Inc, which ended +13.3% after beating third-quarter financial forecasts on higher collaboration profits from its flagship drug Dupixent.

Regeneron's surge also reflected an expanded collaboration agreement with Sanofi. The company saw additional support from strong demand for Libtayo and Eylea HD. The sector found further lift in Vertex Pharmaceuticals Inc, which ended +3.5% as its shares reached an all-time peak of $560.99. The combined weight of those two biopharma giants helped offset widespread declines across the rest of the healthcare universe.

That top-heavy support was critical because steep losses dragged down other corners of the sector, most notably Illumina Inc, which ended -18.6%. Although the genetic sequencing company raised its full-year profit outlook, reported revenue was dampened by tariff-refund charges alongside a 6% drop in research-and-applied consumables sales. Selling intensified as investors focused on softer overseas demand and near-term revenue headwinds, making it the sector's poorest performer on the day.

Across the broader market, Health Care was one of the few groups in the green, as 5 of the 11 sectors rose. For investors tracking the sector through XLV, the vehicle packages that large-cap exposure at an expense ratio of 0.08%, though Friday's split demonstrated how heavily its performance can turn on a handful of mega-caps. Over the past 100 sessions, the fund has posted +20.9%, extending its twelve-month return to +28.1%.